Drug intelligence / Profile preview

AMG 786

Development stage: Discontinued
Lead developer: Amgen
Modality: Small Molecules
Administration: Oral

Overview

AMG 786 is an orally administered small molecule drug that was developed by Amgen for the treatment of obesity. Its precise mechanism of action has not been publicly disclosed. The drug advanced to phase 1 clinical trials, where it was evaluated for safety and tolerability in both healthy volunteers and individuals with obesity. Following completion of these early studies, Amgen discontinued further development of AMG 786 in June 2024 to focus on other assets in its obesity pipeline[1][3][6][7].

Other names: AMG 786AMG786AMG-786

Beyond the preview

Go deeper on AMG 786.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMG 786.

Explore the full profile